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OBJECTIVES: China’s health care expenditure is one of the largest in the world and
is set to grow strongly in the foreseeable future. A greater understanding of the
impact of economic and policy factors on China’s health care expenditure and its
growth trend will help major pharmaceutical firms make strategic plans in the
emerging markets.METHODS: Dynamic least squares regression was used on an-
nual time series data (1970 to 2011). The dependent variable was real per capita
health care expenditure (RPCHE). The explanatory variables included real per cap-
ita GDP (RPCGDP), relative price for consumer health spending (RPCMED) and
lagged variables. The analysis used data fromWHO, China Statistical Yearbook and
IHS Healthcare Forecasting. The main independent variables were RPCGDP and
RPCMED. RESULTS: A negative correlation was found between estimated RPCHE
and RPCMED; and a positive correlation between estimated RPCHE and RPCGDP.
The main results can be summarized as follows: 1) For every 1% rise in the growth
rate of RPCMED, there is a 1.16% decrease in the level of RPCHE, and 2) the income
elasticity of real health care expenditure is 15%. Based on the estimations, forecasts
on total health care expenditureweremade for the forecast period (2012-2020). The
main independent variables—RPCMEDandRPCGDP—were derived from IHSMacro
for the forecast period. To capture health care policy’s impact on health care ex-
penditure, add factors were used in the forecast. According to the forecast, China’s
total health care expenditure is projected to grow 15.8% this year and 14.8% next.
CONCLUSIONS: In terms of economic impact, relative price for consumer health
spending and income play a major role in determining health care expenditure. In
terms of policy impact, China’s health care reform—via massive health insurance
expansion—will be a key driver of health care expenditure growth throughout the
forecast horizon, although there are increasing pressures on pricing and significant
regional disparities.
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OBJECTIVES:To obtain information on spending onprevention and care-treatment
programs among prisoners in two prisons: Jakarta and Bali and who finance the
program. METHODS: Retrospective data was collected from two prisons: Bali and
Jakarta. Cost was estimated from government and partners perspective. Both
quantitative and qualitative analysis were done. A modified activity-based costing
was done supported with document review and interviews. RESULTS: HIV inter-
vention in Indonesia has been improving with support from the Government and
international partners. At the moment several prisons in Java are chosen as model
for HIV-AIDS programs for prisoners, including VCT, Lab-test, ART, OI treatment
and hospital care. Total spending in Bali was USD 26.239 per-year and unit cost was
USD 78, while in Jakarta unit cost was USD 426. These spending even higher if other
activities such as substitution and treatment at hospital were included. Some pro-
grams such as Methadone theraphy, condom and ART were conducted in collabo-
ration with District Health Office and local hospital, and funded by government.
Interestingly, program for prisoners in Bali includes spiritual theraphy such as yoga
and dancing, initiated using funds from international partners. High cost for CD4
and ART were covered by central government, while operational cost was sup-
ported by local government. Networking with other institution become critical,
since no direct costs actually covered by the prisons themselves. CONCLUSIONS:
Most of program intervention for prisoners supported by external partners. Sus-
tainability issue remain unclear since donor fundingwill be finished soon andmust
be replaced by government. Local government is expected to support continuity of
the program, but regions with low fiscal capacity are not able to ensure program
continuity.
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OBJECTIVES: Each year over a million patients in Australia delay seeing a General
Practioner (GP), and a similar number do not fill their prescriptions, because of the
cost. This failure to access necessary medications has economic and morbidity
implications in the long-term. In addition, reduced uptake affects company reve-
nue. Currently theUS Food andDrugAdministration (FDA) is considering a range of
measures to improve access to medicines, including making more drugs used for
common, under-treated conditions, available over-the-counter (OTC). This study
aimed to compare the costs to the patient and potential manufacturer price for a
sample of medicines that are available both OTC and on prescription in Australia.
METHODS: Costs of accessing diclofenac (25mg tablets) and omeprazole (20mg
tablets) via a GP prescription were compared to those for OTC. For medicines ob-
tained on prescription, patient co-payments were sourced from the Pharmaceuti-
cal Benefits Schedule (PBS) website, and the average cost of a GP visit. Costs of OTC
formulations were estimated based on a sample of pharmacies. The resultant cost
to patient and potential price to the manufacturer were calculated and compared.
RESULTS: For patients in Australia, OTC acquisition of medicines was up to 50%
less expensive per tablet than accessing treatment via GP prescription. The per-
tablet savings for patient were greater for omeprazole than for diclofenac. At the
point of sale, the cost per tablet of OTC products was 150%-500% of the ex-manu-
facturer cost for the PBS listed product. Therefore, an OTC strategy also appears to
be a commercially viable for manufacturers, even allowing for a pharmacy
mark-up. CONCLUSIONS: Down-scheduling from prescription-only to OTC may
decrease the direct costs of treatment for patients, while simultaneously increas-
ing the price per tablet to manufacturers: a win-win situation.
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OBJECTIVES: Replacement of Peripheral Venous Catheter (PVC) is sometimes re-
quired prematurely due to extravasation, catheter damage, complications such as
phlebitis. We evaluated the clinical and economic benefits of an integrated closed
intravenous catheter system (CICS) with pre-attached stabilization platform and
extension tube (Catheter A) which may reduce the occurrence of unscheduled
catheter replacement. METHODS: A prospective, open, quasi-random, and con-
trolled study was conducted to compare Catheter A and a conventional PVC (Cath-
eter B) in a 286-bed general hospital in Japan. Patients requiring PVCs for 72 hours
or more were enrolled and assigned to either Catheter A Group (Group A) or Cath-
eter B Group (Group B). Both catheters were secured with the same procedure and
regularly observed until removal. The Kaplan-Meier estimate for the replacement
rates for both catheters for 72 hours was calculated, and the cost difference be-
tween the groups was obtained using product prices and average nursing fees
published by the government. RESULTS: There were 358 patients evaluated: 193 in
Group A and 165 in Group B. One hundred forty three patients in Group A and 109
patients in Group B required catheter replacement because of extravasation, cath-
eter damage, complications, or scheduled catheter removal. The remaining 106
patients from both groups had catheters removed for unexpected reasons such as
earlier end of therapy and self-withdrawal. Excluding those 106 patients, therewas
a significant difference in the catheter survival curves between Group A and B
(p0.01, log-rank test). The total cost of catheter replacement for 72-hour use was
393 yen for Group A and 704 yen for Group B. CONCLUSIONS: The cost difference
between two catheters can be offset by savings generated from a lower event rate.
Along with total cost benefits, the use of CICS is considered to provide improved
safety to patients through decreased complications.
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OBJECTIVES: Febrile neutropenia (FN) is a major complication in cancer patients
treated with chemotherapy, leading to infection-associatedmorbidity andmortal-
ity. Therefore, prophylactic use of granulocyte colony-stimulating factor (G-CSF) is
recommended by recent clinical guidelines tomanage those patientswith high risk
of FN. Uncertainty in selecting patients who need G-CSF prophylaxis, however,
remains in clinical settings. The objectives of this study were to document the
utilization pattern of G-CSF and to analyze the potential risk factors of FN in non-
Hodgkin’s lymphoma (NHL) patients.METHODS: Eligible patients were those who
were older than 18 years, diagnosed with NHL, and initiated a new chemotherapy
regimen in 2010 at amedical center in Taiwan. All chemotherapy cycles received by
our study subjects were divided into two groups based on the occurrence of FN
during each cycle. All patients were followed until all the planned chemotherapy
courses were completed or one year after the first date of chemotherapy regimen.
Differences in patient characteristics between the FN and non-FN group were as-
sessed with chi-square tests for categorical variables and t-tests for continuous
variables. RESULTS: Two hundred and eighty-six courses for G-CSF prophylaxis
were evaluated in 72 patients receiving a total of 432 cycles of chemotherapy reg-
imen. Of these, 38 % of G-CSF was prescribed as primary prophylaxis, and 62 % as
secondary prophylaxis, with an average duration of 3 days. Differences between FN
and non-FN group which is statistically significance were history of chronic renal
failure or anemia (p0.0038, p0.0001), prophylactic use of G-CSF (p0.0192), per-
formance status (p0.0001), numbers of previous neutropenia (p0.0008), baseline
albumin or hemoglobin level (p0.0085, p0.0001). CONCLUSIONS: At this cancer
center in Taiwan, the duration of G-CSF administration is shorter than the recom-
mended. Differences between the two groups may be the possible risk factors, and
need to be further analyzed.
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OBJECTIVES: To compare pharmaceutical company and medical representatives
as drug information source with other conventional and advanced sources being
used by Doctors. METHODS: A total 103 doctors were interviewed personally by
using a structured validated questionnaire developed. Ransom and purposeful
samplingwas used to select the required sample. The data collectedwas evaluated
and represented in the form of total numbers and percentages. RESULTS: Among
103 doctors (52.42% or 54) mentioned that pharmaceutical companies andmedical
representatives are less useful source of information. 58.25% doctors responded
that Pharmaceutical company sponsored Education program as useful. A total of
17.47%mentioned it as very useful source of information for new drugs and 24.27%
doctors mentioned it as less useful. A total of 59.12% doctors mentioned medical
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